IP Verse

Bispecific Antibodies Against Cd3Epsilon And Bcma For Use In Treatment Of Diseases - EP3227333

The patent EP3227333 was granted to Bristol Myers Squibb on Aug 16, 2023. The application was originally filed on Dec 2, 2015 under application number EP15804458A. The patent is currently recorded with a legal status of "Revoked".

EP3227333

BRISTOL MYERS SQUIBB
Application Number
EP15804458A
Filing Date
Dec 2, 2015
Status
Revoked
Aug 22, 2025
Grant Date
Aug 16, 2023
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (3)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

PFIZERMay 16, 2024PFIZERADMISSIBLE
SCORPIOMay 16, 2024SAGITTARIUSADMISSIBLE
J A KEMPMay 14, 2024J A KEMPADMISSIBLE

Patent Citations (16) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
INTERNATIONAL-SEARCH-REPORTWO2009032058
INTERNATIONAL-SEARCH-REPORTWO2012143498
INTERNATIONAL-SEARCH-REPORTWO2013072406
INTERNATIONAL-SEARCH-REPORTWO2014122143
INTERNATIONAL-SEARCH-REPORTWO2014140248
OPPOSITIONEP2982692
OPPOSITIONWO2009132058
OPPOSITIONWO2012143498
OPPOSITIONWO2013026839
OPPOSITIONWO2013072406
OPPOSITIONWO2013072415
OPPOSITIONWO2014122143
OPPOSITIONWO2014122144
OPPOSITIONWO2014131712
OPPOSITIONWO2014140248
OPPOSITIONWO2014167022

Non-Patent Literature (NPL) Citations (32) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
OPPOSITION- Anonymous, "B-Cell Development and Activation", Biolegend, The path to legendary discovery, (20100101), pages 1 - 1, XP093190492
OPPOSITION- Anonymous, "Phase I Dose Escalation of i.v. BI 836909 Monotherapy in Last Line Multiple Myeloma Patients", Clinical Trials, NCT02514239, (20220224), pages 1 - 14, XP093190606
OPPOSITION- Declaration of Jean Francois Rossi
OPPOSITION- GARFALL ALFRED L ET AL, "Immunotherapy with chimeric antigen receptors for multiple myeloma.", Discovery medicine : medicine on the leading edge, Discovery Medicine, US, US , (20140101), vol. 17, no. 91, ISSN 1944-7930, pages 37 - 46, XP002733374
OPPOSITION- invitrogen, "CD3 Monoclonal Antibody (UCHT1), eBioscience™", Product Datasheet, pages 1 - 3
OPPOSITION- Jean-Francois Rossi CV
OPPOSITION- LÖFFLER A, ET AL, "A recombinant bispecific single-chain antibody, CD19 x CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes.", Blood, American Society of Hematology, US, US , (20000315), vol. 95, no. 6, ISSN 0006-4971, pages 2098 - 2103, XP002572419
OPPOSITION- Ramadoss Nitya S, Schulman Andrew D, Choi Sei-Hyun, Rodgers David T, Kazane Stephanie A, Kim Chan Hyuk, Lawson Brian R, Young Travis S, "Supporting Information: An Anti‑B Cell Maturation Antigen Bispecific Antibody for Multiple Myeloma", JACS, (20150101), pages S1 - S12, XP093191976
OPPOSITION- RYAN MAUREEN C, ET AL, "Antibody targeting of B-cell maturation antigen on malignant plasma cells.", Molecular Cancer Therapeutics, American Association for Cancer Research, US, US , (20071101), vol. 6, no. 11, ISSN 1535-7163, pages 3009 - 3018, XP002581270
OPPOSITION- HOFFMANN PATRICK ET AL, "Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-/CD3-bispecific single-chain antibody construct.", International Journal of Cancer, John Wiley & Sons, Inc., US, US , (20050520), vol. 115, no. 1, doi:10.1002/ijc.20908, ISSN 0020-7136, pages 98 - 104, XP002335808
OPPOSITION- Foureau David M., Bhutani Manisha, Robinson Myra, Guo Fei, Pham Duy, Buelow Ben, Steuerwald Nury, Rigby Katherine, Tjaden Elise, Leonidas Marina, Paul Barry A., Atrash Shebli, Ndiaye Ami, Symanowski James T., Voorhees Peter M., Usmani Saad Z., "Ex vivo efficacy of BCMA‐bispecific antibody TNB‐383B in relapsed/refractory multiple myeloma", eJHaem, (20200701), vol. 1, no. 1, doi:10.1002/jha2.69, ISSN 2688-6146, pages 113 - 121, XP093190497
OPPOSITION- Seckinger Anja et al, "Target Expression, Generation, Preclinical Activity, and Pharmacokinetics of the BCMA-T Cell Bispecific Antibody EM801 for Multiple Myeloma Treatment", CANCER CELL, CELL PRESS, US, US , (20170302), vol. 31, no. 3, doi:10.1016/j.ccell.2017.02.002, ISSN 1535-6108, pages 396 - 410, XP029953443
OPPOSITION- Friedrich Mirco J.; Neri Paola; Kehl Niklas; Michel Julius; Steiger Simon; Kilian Michael; Leblay Noémie; Maity Ranjan; Sankowski Roman; Lee Holly; Barakat Elie; Ahn Sungwoo; Weinhold Niels; Rippe Karsten; Bunse Lukas; Platten Michael; Goldschmidt Hartmut; Müller-Tidow Carsten; Raab Marc-Steffen; Bahlis Nizar J., "The pre-existing T cell landscape determines the response to bispecific T cell engagers in multiple myeloma patients", CANCER CELL, CELL PRESS, US, US , (20230309), vol. 41, no. 4, doi:10.1016/j.ccell.2023.02.008, ISSN 1535-6108, page 711, XP087294746
OPPOSITION- Nitya S. Ramadoss et al., "An Anti-B Cell Maturation Antigen Bispecific Antibody for Multiple Myeloma", Journal of the American Chemical Society, (2015), vol. 137, doi:10.1021/jacs.5b01876, XP055572577
OPPOSITION- Dosani T, Carlsten M, Maric I, Landgren O, "The cellular immune system in myelomagenesis: NK cells and T cells in the development of MM and their uses in immunotherapies", Blood Cancer Journal, Nature Publishing Group, GB, GB , (2015), vol. 5, no. e306, doi:10.1038/bcj.2015.32, ISSN 2044-5385, pages 1 - 9, XP093190483
OPPOSITION- D Honemann et al., "A novel recombinant bispecific single-chain antibody, bscWue-1 x CD3, induces T-cell-mediated cytotoxicity towards human multiple myeloma cells", Leukemia, (20040122), vol. 18, doi:10.1038/sj.leu.2403264, XP037782441
OPPOSITION- D. Honemann et al., "A novel recombinant bispecific single-chain antibody, bscWue-1 x CD3, induces T-cell-mediated cytotoxicity towards human multiple myeloma cells", Leukemia, (2004), vol. 18, doi:10.1038/sj.leu.2403264, XP055741420
OPPOSITION- Hönemann D. et al, "A novel recombinant bispecific single-chain antibody, bscWue-1 × CD3, induces T-cell-mediated cytotoxicity towards human multiple myeloma cells", Blood Cancer Journal, Nature Publishing Group UK, London, London, (20040122), vol. 18, no. 3, doi:10.1038/sj.leu.2403264, ISSN 0887-6924, pages 636 - 644, XP037782441
OPPOSITION- Ulrich H. Weidle et al, "Tumor-Antigen–Binding Bispecific Antibodies for Cancer Treatment", Seminars in Oncology, W.B. Saunders, (20141001), vol. 41, no. 5, doi:10.1053/j.seminoncol.2014.08.004, ISSN 0093-7754, pages 653 - 660, XP055250095
OPPOSITION- Eric Sanchez et al, "Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival", British Journal of Haematology, (20120901), vol. 158, no. 6, doi:10.1111/j.1365-2141.2012.09241.x, ISSN 00071048, pages 727 - 738, XP055186278
OPPOSITION- Eric Sanchez et al., "Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival", British Journal of Haematology, (2012), vol. 158, doi:10.1111/j.1365-2141.2012.09241.x, XP055186278
OPPOSITION- Eric Sanchez; Mingjie Li; Alex Kitto; Jennifer Li; Cathy S. Wang; Dylan T. Kirk; Ori Yellin; Cydney M. Nichols; Marissa P. Dreyer; Cameryn P. Ahles; Austin Robinson; Erik Madden; Gabriel N. Waterman; Regina A. Swift; Benjamin Bonavida; Ralph Boccia; Robert A. Vescio; John Crowley; Haiming Chen; James R. Berenson, "Serum B‐cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival", British Journal of Haematology, John Wiley, Hoboken, USA, Hoboken, USA, (20120718), vol. 158, no. 6, doi:10.1111/j.1365-2141.2012.09241.x, ISSN 0007-1048, pages 727 - 738, XP071161456
OPPOSITION- Panowski et al, "Preclinical Efficacy and Safety Comparison of CD3 Bispecific and ADC Modalities Targeting BCMA for the Treatment of Multiple Myeloma", Molecular cancer therapeutics, (20191101), vol. 18, no. 11, doi:10.1158/1535-7163.MCT-19-0007, pages 1 - 13, XP055718531
OPPOSITION- J. Moreaux, Eric Legouffe, Eric Jourdan, Philippe Quittet, Thierry Rè, Cé Cile Lugagne, Philippe Moine, Jean-François Rossi, Bernard Klein, Karin Tarte, "BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone", Blood, American Society of Hematology, US, US , (20040415), vol. 103, no. 8, doi:10.1182/blood-2003-06-1984, ISSN 0006-4971, pages 3148 - 3157, XP055275026
OPPOSITION- J. Moreaux et al, "BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone", Blood, American Society of Hematology, US, US , (20040415), vol. 103, no. 8, doi:10.1182/blood-2003-06-1984, ISSN 0006-4971, pages 3148 - 3157, XP055275026
OPPOSITION- A. J. Novak, "Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival", Blood, (20040115), vol. 103, no. 2, doi:10.1182/blood-2003-06-2043, ISSN 00064971, pages 689 - 694, XP055004448
OPPOSITION- Leiba Merav; Xu Jiangchun; Song Weihua; Li Xian-Feng; Burger Peter; Kordich Jennifer; Cassiano Linda; Podar Klaus; Chauhan Dharminder; Hideshima Teru; Munshi Nikhil C.; Richardson Paul; Anderson Kenneth C.; Tai Yu-Tzu, "Activation of B-Cell Maturation Antigen (BCMA) on Human Multiple Myeloma Cells by a Proliferation-Inducing Ligand (APRIL) Promotes Myeloma Cell Function in the Bone Marrow Microenvironment.", Blood, American Society of Hematology, US, US , (20071116), vol. 110, no. 11, doi:10.1182/blood.V110.11.1503.1503, ISSN 0006-4971, page 1503, XP086644166
OPPOSITION- Hipp Susanne et al, "BI 836909, a Novel Bispecific T Cell Engager for the Treatment of Multiple Myeloma Induces Highly Specific and Efficacious Lysis of Multiple Myeloma Cells in Vitro and Shows Anti-Tumor Activity in Vivo", Blood, American Society of Hematology, US, US , (20151203), vol. 126, no. 23, doi:10.1182/blood.V126.23.2999.2999, ISSN 0006-4971, page 2999, XP086651056
OPPOSITION- Zelle-Rieser Claudia, Thangavadivel Shanmugapriya, Biedermann Rainer, Brunner Andrea, Stoitzner Patrizia, Willenbacher Ella, Greil Richard, Jöhrer Karin, "T cells in multiple myeloma display features of exhaustion and senescence at the tumor site", Journal of Hematology & Oncology, BioMed Central Ltd, London UK, London UK , (20161201), vol. 9, no. 1, doi:10.1186/s13045-016-0345-3, ISSN 1756-8722, XP093191970
OPPOSITION- Paíno Teresa, Sarasquete María E., Paiva Bruno, Krzeminski Patryk, San-Segundo Laura, Corchete Luis A., Redondo Alba, Garayoa Mercedes, García-Sanz Ramón, Gutiérrez Norma C., Ocio Enrique M., San-Miguel Jesús F., "Phenotypic, Genomic and Functional Characterization Reveals No Differences between CD138++ and CD138low Subpopulations in Multiple Myeloma Cell Lines", PLOS ONE, Public Library of Science, US, US , (20140321), vol. 9, no. 3, doi:10.1371/journal.pone.0092378, ISSN 1932-6203, page e92378, XP093191572
OPPOSITION- Parrish Christopher, Scott Gina B, Cook Gordon, "Immune Dysfunction in Multiple Myeloma", International Journal of Hematologic Oncology, Future Medicine Ltd, GB, GB , (20130201), vol. 2, no. 1, doi:10.2217/ijh.12.33, ISSN 2045-1393, pages 49 - 59, XP093190487
OPPOSITION- Pinto Vanessa et al, "Multiple Myeloma: Available Therapies and Causes of Drug Resistance", Cancers, MDPI AG, CH, CH , (2020), vol. 12, no. 407, doi:10.3390/cancers12020407, ISSN 2072-6694, pages 1 - 32, XP093190479

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents